Form 4: United Therapeutics Exec Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving common stock and stock options on April 10, 2026.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, engaged in several transactions on April 10, 2026.
• These transactions included the acquisition of 9,500 shares of common stock at an average price of $146.03, and the disposal of 442 shares at a weighted average price of $567.24, among other sales.
• The acquisition of shares was linked to the exercise of stock options.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• The 10b5-1 plan is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Rothblatt beneficially owns a significant number of shares indirectly through various trusts and by her spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine insider transactions under a pre-established plan rather than a significant strategic event or performance indicator.

Positives

• Acquisition of 9,500 shares of common stock at $146.03 per share, indicating continued investment or option exercise.
• The transactions were executed under a Rule 10b5-1 trading plan, suggesting a structured and pre-determined approach to stock transactions, which can mitigate insider trading concerns.
• The reporting person holds a substantial number of shares indirectly, indicating long-term commitment and diversified ownership structures.

Negatives

• Disposal of a significant number of shares through multiple transactions at prices ranging from $566.44 to $573.11.
• The weighted average sale price of $567.24 for 442 shares is considerably higher than the acquisition price of $146.03 for the 9,500 shares, suggesting a sale of previously acquired shares at a profit.

Risks

• The 10b5-1 trading plan has an expiration date of December 31, 2026, or upon exercise of all remaining options, creating a defined window for these transactions.
• The reporting person's beneficial ownership is spread across various trusts, which could introduce complexity in understanding direct control and intent.

Future Outlook

The 10b5-1 trading plan is active until December 31, 2026, or until all 1,734,410 stock options are exercised, indicating ongoing potential for stock transactions within this period.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO like Martine Rothblatt at United Therapeutics is a common strategy to manage personal stock sales in a way that complies with regulations and avoids perceptions of insider trading, especially for companies in the biotechnology sector where stock prices can be volatile.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive may be interpreted in various ways, but the use of a 10b5-1 plan suggests a structured approach to avoid negative perceptions.
• Employees: The transactions do not directly impact employee stock options or benefits but reflect executive compensation and wealth management.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continue to monitor transactions under the 10b5-1 plan until its expiration or completion of option exercises.
• Observe future filings for any further changes in beneficial ownership or new trading plans.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Common Stock, 10b5-1 Plan, United Therapeutics, UTHR, Martine Rothblatt, Beneficial Ownership, Stock Transactions